PIK-93 NEW
| Price | $82 | $113 | $222 |
| Package | 5mg | 10mg | 25mg |
| Supply Ability: | 10g |
| Update Time: | 2026-04-22 |
Product Details
| Product Name: PIK-93 | CAS No.: 593960-11-3 |
| Purity: 99.83% | Supply Ability: 10g |
| Release date: 2026/04/22 |
Product Introduction
Bioactivity
| Name | PIK-93 |
| Description | PIK-93, the first potent synthetic PI4K inhibitor, exhibits an IC50 of 19 nM and also inhibits PI3Kα with an IC50 of 39 nM. |
| Cell Research | For actin staining, dHL60 cells are preincubated in suspension with PIK-93 or vehicle for 40 min, centrifuged for 5 min at 2000 rpm at room temperature in a J6-B centrifuge, resuspended in mHBSS containing the respective agent at the same concentration, allowed to stick to fibronectin-covered coverslips, and subjected to stimulation with a uniform concentration of 100 nM f-Met-Leu-Phe (fMLP) for 3 min. Cellsare fixed in 3.7% PFA and stained with 10 units/mL rhodamine-phalloidin for 15 min.(Only for Reference) |
| Kinase Assay | Assay of PI3Ks: IC50 values are measured using a standard TLC assay for lipid kinase activity. Kinase reactions are performed by preparing areaction mixture containing kinase, PIK-93 (2% DMSO final concentration), buffer (25 mM HEPES, pH 7.4, 10 mM MgCl2), and freshly sonicated phosphatidylinositol (100 μg/ml). Reactions are initiated by the addition of ATP containing 10 μCi of γ-32P-ATP to a final concentration 10 or 100 μM, and allowed to proceed for 20 min at room temperature. For TLC analysis, reactions are then terminated by the addition of 105 μL 1N HCl followed by 160 μL CHCl3:MeOH (1:1). The biphasic mixture is vortexed, briefly centrifuged, and the organic phase transferred to a new tube using a gel loading pipette tip precoated with CHCl3. This extract is spotted on TLC plates and developed for 3 hours–4 hours in a 65:35 solution of n-propanol:1M acetic acid. The TLC plates are then dried, exposed to a phosphorimager screen, and quantitated. Kinase activity is typically measured at 10–12 concentrations of PIK-93 representing two-fold dilutions from the highest concentration of 100 μM. |
| In vivo | At concentrations ranging from 0.5 μM to 1 μM, PIK-93 impairs the stability of aggregates formed in differentiated HL60 cells treated with f-Met-Leu-Phe. In COS-7 cells, 250 nM of PIK-93 effectively eliminates the accumulation of the CERT-PH domain and FL-Cer in the Golgi apparatus. Additionally, in T6.11 cells, 300 nM of PIK-93 reduces Carbachol-induced translocation of TRPC6 to the plasma membrane and subsequent Ca2+ entry. The same concentration of PIK-93 also significantly inhibits the conversion of [3H]-labeled serine to endogenous sphingomyelin, indicating the critical role of PI4KIIIβ in the endoplasmic reticulum and Golgi apparatus for ceramide transfer and sphingomyelin synthesis regulation. Research demonstrates that PIK-93 possesses antiviral capabilities, inhibiting replication of the poliovirus and hepatitis C virus with EC50 values of 0.14 μM and 1.9 μM, respectively. PIK-93 effectively inhibits PI3Kγ and PI4KIIIβ, with IC50 values of 16 nM and 19 nM, respectively, and other PI3K members, including PI3Kα, β, and δ, with IC50 values of 39 nM, 0.59 μM, and 0.12 μM, while showing negligible inhibition effects on other kinases at concentrations up to 10 μM. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 39 mg/mL (100.03 mM), Sonication is recommended. 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 4 mg/mL (10.26 mM), Sonication is recommended. |
| Keywords | VirusProtease | Virus Protease | PIK-93 | PIK93 | PI4K | PI4 kinases | PI3KIIIβ | PI3K | Phosphoinositide 3-kinase | Phosphatidylinositol 4 kinases | p110δ | p110γ | p110β | p110α | mTORC1 | Inhibitor | inhibit | hsVps34 | DNA-PK | DNAPK | CarbonicAnhydrase | Carbonic Anhydrase | C2β | ATR | ATM |
| Inhibitors Related | Musk ketone | Urea | Phenytoin sodium | Sodium Dihydrogen Phosphate | Myricetin | Hyaluronic acid | L-Lysine | L-Lysine hydrochloride | Oxyresveratrol | Vidarabine | Thymidine | Methyl eugenol |
| Related Compound Libraries | Anti-Colorectal Cancer Compound Library | Bioactive Compound Library | HIF-1 Signaling Pathway Compound Library | Kinase Inhibitor Library | Autophagy Compound Library | Anti-Viral Compound Library | Inhibitor Library | Anti-Fibrosis Compound Library | Anti-Aging Compound Library | Immunology/Inflammation Compound Library | Bioactive Compounds Library Max | Anti-Metabolism Disease Compound Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $573.00 |
VIP2Y
|
TargetMol Chemicals Inc.
|
2026-05-11 | |
|
VIP6Y
|
RongNa Biotechnology Co.,Ltd
|
2026-06-06 | ||
|
VIP3Y
|
ShenZhen H&D Pharmaceutical Technology Co., LTD
|
2026-03-12 | ||
| $2.00 |
VIP8Y
|
Career Henan Chemical Co
|
2019-07-06 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, MA
INQUIRY